BR112019003957A2 - proteína de ligação a fator h modificado - Google Patents

proteína de ligação a fator h modificado

Info

Publication number
BR112019003957A2
BR112019003957A2 BR112019003957A BR112019003957A BR112019003957A2 BR 112019003957 A2 BR112019003957 A2 BR 112019003957A2 BR 112019003957 A BR112019003957 A BR 112019003957A BR 112019003957 A BR112019003957 A BR 112019003957A BR 112019003957 A2 BR112019003957 A2 BR 112019003957A2
Authority
BR
Brazil
Prior art keywords
modified
binding protein
factor binding
fhbp
relates
Prior art date
Application number
BR112019003957A
Other languages
English (en)
Portuguese (pt)
Inventor
M Tang Christoph
Original Assignee
Univ Oxford Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oxford Innovation Ltd filed Critical Univ Oxford Innovation Ltd
Publication of BR112019003957A2 publication Critical patent/BR112019003957A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
BR112019003957A 2016-08-31 2017-08-31 proteína de ligação a fator h modificado BR112019003957A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1614687.0A GB201614687D0 (en) 2016-08-31 2016-08-31 fHbp scaffold
PCT/GB2017/052535 WO2018042178A1 (en) 2016-08-31 2017-08-31 Modified factor h binding protein

Publications (1)

Publication Number Publication Date
BR112019003957A2 true BR112019003957A2 (pt) 2019-06-25

Family

ID=57119942

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019003957A BR112019003957A2 (pt) 2016-08-31 2017-08-31 proteína de ligação a fator h modificado

Country Status (13)

Country Link
US (1) US12497432B2 (enExample)
EP (1) EP3506934A1 (enExample)
JP (1) JP7525093B2 (enExample)
KR (1) KR102643280B1 (enExample)
CN (1) CN109890412B (enExample)
AU (1) AU2017319218B2 (enExample)
BR (1) BR112019003957A2 (enExample)
CA (1) CA3035159A1 (enExample)
GB (2) GB201614687D0 (enExample)
IL (1) IL265078B2 (enExample)
MX (1) MX420767B (enExample)
WO (1) WO2018042178A1 (enExample)
ZA (1) ZA201901862B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201614687D0 (en) * 2016-08-31 2016-10-12 Univ Oxford Innovation Ltd fHbp scaffold
CN110903400A (zh) * 2019-11-08 2020-03-24 苏州微超生物科技有限公司 B群脑膜炎球菌fHBP多变体融合蛋白及其制备方法与应用
CN111533792B (zh) 2020-07-07 2020-10-16 康希诺生物股份公司 一种定点突变的载体蛋白及其在制备疫苗中的用途
WO2022071291A1 (ja) * 2020-09-29 2022-04-07 出光興産株式会社 ペプチドタグおよびそれを含むタグ付加タンパク質
IN202321021121A (enExample) * 2023-03-24 2024-04-19

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX339524B (es) * 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US7351413B2 (en) * 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
DK2353608T3 (da) * 2002-10-11 2020-02-10 Novartis Vaccines And Diagnostics S R L Polypeptid-vacciner til bred beskyttelse mod hypervirulente meningokok-linjer
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
KR100991679B1 (ko) * 2002-12-10 2010-11-04 셀덱스 테라퓨틱스 리미티드 안정화 면역원성 ＨＢｃ 키메라 입자
DK1587537T3 (da) * 2003-01-30 2012-07-16 Novartis Ag Injicerbare vacciner mod multiple meningococ-serogrupper
SI1670506T1 (sl) * 2003-10-02 2013-03-29 Novartis Ag Tekoča cepiva proti multiplim meningokoknim seroskupinam
GB0408977D0 (en) * 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB2414667A (en) * 2004-06-03 2005-12-07 Isis Innovation Vaccine compositions of N. meningitidis PorA and FetA antigens
CA2574375C (en) * 2004-07-23 2015-03-17 Chiron Srl Polypeptides for oligomeric assembly of antigens
GB0419408D0 (en) * 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
SI2682126T1 (sl) * 2005-01-27 2017-03-31 Children's Hospital & Research Center At Oakland Cepiva na osnovi veziklov, osnovanih na GNA1870, za širokospektralno zaščito proti boleznim, povzročenim z Neisserio meningitidisom
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
EP1925318A1 (en) * 2006-11-20 2008-05-28 Paul-Ehrlich-Institut Recombinant modified vaccinia virus Ankara (MVA)-based vaccine for the avian flu
WO2009104097A2 (en) * 2008-02-21 2009-08-27 Novartis Ag Meningococcal fhbp polypeptides
AU2009223613B2 (en) * 2008-03-10 2014-09-25 Children's Hospital & Research Center At Oakland Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
WO2009158142A1 (en) * 2008-05-30 2009-12-30 The U.S.A., As Represented By The Secretary Of The Army, On Behalf Of Walter Reed Army Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof
WO2009150531A1 (en) * 2008-06-09 2009-12-17 Novartis Ag Antibodies against neisserial factor h binding protein
AU2009288095A1 (en) * 2008-09-03 2010-03-11 Children's Hospital & Research Center At Oakland Peptides presenting an epitope of a domain of factor H binding protein and methods of use
GB0819633D0 (en) * 2008-10-25 2008-12-03 Isis Innovation Composition
CA2756522C (en) * 2009-03-24 2018-06-26 Novartis Ag Adjuvanting meningococcal factor h binding protein
WO2010127172A2 (en) * 2009-04-30 2010-11-04 Children's Hospital & Research Center At Oakland Chimeric factor h binding proteins (fhbp) and methods of use
CN102596240B (zh) * 2009-08-27 2015-02-04 诺华股份有限公司 包括脑膜炎球菌fHBP序列的杂交多肽
US20130022633A1 (en) * 2009-10-27 2013-01-24 University Of Florence MENINGOCOCCAL fHBP POLYPEPTIDES
JP2013521326A (ja) * 2010-03-10 2013-06-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
BR122021020829B8 (pt) * 2010-03-30 2022-12-27 Children´S Hospital & Res Center At Oakland Proteína de ligação ao fator h de ocorrência não natural (fhbp), composição, e célula hospedeira de neisseria meningitidis geneticamente modificada
US9073990B2 (en) * 2010-04-05 2015-07-07 Bar-Llan University Protease-activatable pore-forming polypeptides
US10478483B2 (en) * 2010-06-25 2019-11-19 Glaxosmithkline Biologicals Sa Combinations of meningococcal factor H binding proteins
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
RU2546873C2 (ru) * 2010-09-10 2015-04-10 УАЙТ ЭлЭлСи Нелипидизированные варианты антигенов neisseria meningitidis orf2086
WO2013078223A1 (en) * 2011-11-23 2013-05-30 Children's Hospital & Research Center Oakland Anti-factor h binding protein antibodies and methods of use thereof
CA2862247A1 (en) * 2011-12-29 2013-07-04 Novartis Ag Adjuvanted combinations of meningococcal factor h binding proteins
EP2823312B1 (en) * 2012-03-08 2019-08-07 GlaxoSmithKline Biologicals SA In vitro potency assay for protein-based meningococcal vaccines
SA115360586B1 (ar) * 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MY167723A (en) * 2012-03-09 2018-09-21 Pfizer Neisseria meningitidis compositions and methods thereof
WO2013186753A1 (en) * 2012-06-14 2013-12-19 Novartis Ag Vaccines for serogroup x meningococcus
GB201215005D0 (en) * 2012-08-23 2012-10-10 Isis Innovation Stabilised meningitis vaccine
US9802987B2 (en) * 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
US20160030544A1 (en) * 2013-03-14 2016-02-04 Isis Innovation Limited Immunogenic composition to neisseria
EP4098276A1 (en) * 2013-09-08 2022-12-07 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
AU2015222121B2 (en) * 2014-02-28 2018-01-18 Glaxosmithkline Biologicals Sa Modified meningococcal fHbp polypeptides
KR102761870B1 (ko) * 2014-07-23 2025-02-05 칠드런즈 하스피틀 앤드 리써치 센터 앳 오클랜드 인자 h 결합 단백질 변이체 및 이의 사용 방법
WO2016083583A1 (en) * 2014-11-28 2016-06-02 Crucell Holland B.V. Meningitis b vaccine
US10888611B2 (en) * 2015-02-19 2021-01-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
GB201614687D0 (en) * 2016-08-31 2016-10-12 Univ Oxford Innovation Ltd fHbp scaffold
PE20191107A1 (es) * 2017-01-31 2019-08-26 Pfizer Composiciones de neisseria meningitidis y metodos respectivos

Also Published As

Publication number Publication date
GB201614687D0 (en) 2016-10-12
MX420767B (es) 2025-02-10
GB2568440B (en) 2022-08-17
NZ751995A (en) 2024-03-22
CN109890412A (zh) 2019-06-14
MX2019002248A (es) 2019-09-18
WO2018042178A1 (en) 2018-03-08
CN109890412B (zh) 2025-04-04
JP2019526261A (ja) 2019-09-19
IL265078A (enExample) 2019-04-30
IL265078B1 (en) 2023-04-01
CA3035159A1 (en) 2018-03-08
KR20190064577A (ko) 2019-06-10
ZA201901862B (en) 2020-09-30
JP7525093B2 (ja) 2024-07-30
AU2017319218B2 (en) 2021-10-28
AU2017319218A2 (en) 2019-05-02
GB201903866D0 (en) 2019-05-08
US12497432B2 (en) 2025-12-16
US20220112249A1 (en) 2022-04-14
KR102643280B1 (ko) 2024-03-05
AU2017319218A1 (en) 2019-04-18
EP3506934A1 (en) 2019-07-10
IL265078B2 (en) 2023-08-01
GB2568440A (en) 2019-05-15

Similar Documents

Publication Publication Date Title
BR112019003957A2 (pt) proteína de ligação a fator h modificado
PH12020550051A1 (en) Glp-1 compositions and uses thereof
BR112018073761A2 (pt) proteínas de ligação ao cd3 de fragmento variável de cadeia única
EA201892489A1 (ru) Число мишеней для мультиплексной оптимизированной амплификации с несоответствиями (moma)
BR112018076190A2 (pt) ortólogos e sistemas crispr tipo vi
AU2016240220B2 (en) Designed ankyrin repeat domains with binding specificity for serum albumin
MX383537B (es) Mutantes de proteína f de rsv.
EP4631970A3 (en) Nucleic acid molecules and uses thereof
EA201891201A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890050A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890049A1 (ru) Композиции, содержащие бактериальные штаммы
BR112016028288A2 (pt) ?composto, composição farmacêutica, métodos para tratamento de um indivíduo com uma doença ou condição e para inibir a quinase, e, uso de um composto?
EA201891399A1 (ru) Бипиразолильные производные, пригодные для лечения аутоиммунных заболеваний
SG10201908839QA (en) 2,4-dihydroxy-nicotinamides as apj agonists
BR112017001417A2 (pt) variantes de proteína de ligação ao fator h e métodos para uso das mesmas
WO2017053732A3 (en) Composition and method for treating complement-mediated disease
MX385972B (es) Partículas y composiciones de nicotina.
MX2021004331A (es) Composiciones estables de semaglutida y usos de las mismas.
WO2018226992A8 (en) Tau aggregation inhibitors
WO2014151982A3 (en) Arginine deiminase with reduced cross-reactivity toward adi – peg 20 antibodies for cancer treatment
EP4218736A3 (en) Compositions comprising 15-hepe
BR112016026842A2 (pt) preparação compreendendo fator viii e peptídeos de fator de von willebrand
EP4574207A3 (en) Means and methods for treating copper-related diseases
MX2017008567A (es) Dnasa modificada y usos de la misma.
MX2020008125A (es) Composiciones que comprenden berberina.

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]